Jade Biosciences, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Jade Biosciences, Inc. pe ratio for the quarter ending 2026-06-30 was -9.21, a change of -5.7 year-over-year.
- Jade Biosciences, Inc. pe ratio for the quarter ending 2026-03-31 was -5.34, a change of 24.53 year-over-year.
- Jade Biosciences, Inc. pe ratio for the quarter ending 2025-12-31 was -5.97, a change of -1.12 year-over-year.
- Jade Biosciences, Inc. pe ratio for the quarter ending 2025-09-30 was -2.76, a change of 22.01 year-over-year.
- Jade Biosciences, Inc. pe ratio for fiscal 2026 was -9.21.
- Jade Biosciences, Inc. pe ratio for fiscal 2025 was -5.97, a change of -1.12 from fiscal 2024.
- Jade Biosciences, Inc. pe ratio for fiscal 2024 was -4.85, a change of 286.32 from fiscal 2023.
- Jade Biosciences, Inc. pe ratio for fiscal 2023 was -291.17, a change of 201.02 from fiscal 2022.
- Available history
- 2021-06-30 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |